2025.09.10
MediaG&E Herbal Biotechnology Featured in Commercial Times
Selected in the Top 100 Foreign Investment Companies in Taiwan
Won three major awards: "Mid-sized Potential Enterprises," "Top 10 Growth," and "Top 10 Profitability"
Report Link: https://reurl.cc/ax89rQ
G&E Herbal Biotechnology was honored in the 2025 Foreign Investment Taiwan Top 100, winning three major awards—Mid-tier Potential Enterprise, Top 10 Growth, and Top 10 Profitability. The company, led by Chairman Kou-Wha, Kuo, is recognized for its innovative plant-based drug development and strong future potential. Its flagship liver-protection medicine “Hepanamin®,” approved by Taiwan’s Ministry of Health, stands out with a world-leading absorption rate of 92–99% for silymarin, surpassing international benchmarks. With over 30 dedicated pharmacies in Taiwan and expansion into Japan, G&E continues to showcase its growth, profitability, and commitment to sustainable innovation.
✔ SR-100 Global Exclusive Patent
✔ Patents in the U.S., Japan, South Korea, Germany, France, the European Union, and dozens of other countries
✔ Patent technology using 100% natural plant extracts
✔ Highly effective breakthrough with high absorption rate for consumption
✔ Scientific research overcoming existing treatment barriers
✔ Manufactured in a PIC/S GMP certified pharmaceutical plant with high standards and product quality
✔ Comprehensive, precise, and effective health protection expert
